Scaling Renal Function in Neonates and Infants to Describe the Pharmacodynamics of Antibiotic Nephrotoxicity

Similar documents
Development and Evaluation of Bayesian Software for Improving Therapeutic Drug Monitoring of Gentamicin in Neonates

Environmental Variability

PKPD Changes with Age

Children are small adults and babies are young children

Brian Anderson, Starship Hospital, Auckland, New Zealand. Shu Chin Ma, University of Auckland, New Zealand

ZIN EN ONZIN VAN ANTIBIOTICASPIEGELS BIJ NEONATEN

PHA First Exam Fall 2003

Renal Impairment From Dettli to Guideline: What can we learn?

Clinical Pharmacology

Comparing Methods for Once Daily Tobramycin Exposure Predictions in Children with Cystic Fibrosis

Target Concentration Intervention

Disease Progress. Clinical Pharmacology = Disease Progress + Drug Action. Outline. Parkinson s Disease. Interpretation of ELLDOPA

PHA Spring First Exam. 8 Aminoglycosides (5 points)

Cystatin C: A New Approach to Improve Medication Dosing

PHA Second Exam Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Basic Pharmacokinetics and Pharmacodynamics: An Integrated Textbook with Computer Simulations

Paediatric Pharmacology: anaesthetic implications

Clinical Pharmacology. Clinical Pharmacology = Disease Progress + Drug Action. Outline. Disease Progress and Drug Action

ICU Volume 11 - Issue 3 - Autumn Series

= (6000 ml air / min * 0.04 ml CO 2 / ml air) / 54 ml CO 2 / dl plasma

Rational Dose Prediction. Pharmacology. φαρμακον. What does this mean? pharmakon. Medicine Poison Magic Spell

51 st Annual Scientific Meeting, Australasian Association of Clinical Biochemists,

1. Immediate 2. Delayed 3. Cumulative

PHA First Exam. Fall 2004

DEVELOPMENTAL PK/PD: WHAT HAVE WE LEARNT? Geoff Tucker

Drug dosing in Extremes of Weight

PHA 5127 FINAL EXAM FALL On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Use of PBPK in simulating drug concentrations in pediatric populations: Case studies of Midazolam and Gabapentin

PHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

CLINICAL TRIAL SIMULATION & ANALYSIS

Delayed Drug Effects. Distribution to Effect Site. Physiological Intermediate

PHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Pediatric Drug Development Current Challenges

Full title of guideline INTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS. control

Counties in the top and bottom two quintiles of both diabetes and obesity, Age-adjusted percentage of adults aged 20 years who are obese, 2007

Lessons from recent studies. João Gonçalves Pereira UCIP DALI

Basic Pharmacokinetic Principles Stephen P. Roush, Pharm.D. Clinical Coordinator, Department of Pharmacy

Drug Disposition in Obesity & Protein-Calorie Malnutrition

General Principles of Pharmacology and Toxicology

Pharmacotherapy Issues in the Pediatric Population

Editorial Intravenous neonatal paracetamol dosing: the magic of 10 days

Pharmacokinetics in pediatric population

Population Pharmacokinetics and Pharmacodynamics as a Tool in Drug Development. Leon Aarons Manchester Pharmacy School University of Manchester

Variation in drug responses & Drug-Drug Interactions

Aminoglycosides John A. Bosso, Pharm.D.

Clinical pharmacology of propylene glycol in neonates

PHA5128 Dose Optimization II Case Study I Spring 2013

Vancomycin Pharmacokinetics in Normal and Morbidly Obese Subjects

Renal Function. 1. Glomerular filtration 2. Active tubular secretion 3. Passive tubular reabsorption 4. Excretion

MODEL-BASED DOSE INDIVIDUALIZATION APPROACHES USING BIOMARKERS

PHARMONITOR II. Optimisation of aminoglycosides dosage regimen with pharmacokinetics modeling. Pierre Wallemacq

Clinical Guidelines for Use of Antibiotics. VANCOMYCIN (Adult)

Product: Omecamtiv Mecarbil Clinical Study Report: Date: 02 April 2014 Page 1

Chapter-V Drug use in renal and hepatic disorders. BY Prof. C.Ramasamy, Head, Dept of Pharmacy Practice SRM College of Pharmacy, SRM University

A Computer-based Pharmacokinetic Implementation for Digoxin Therapeutic Monitoring in Pediatric Patients

Osnove farmakokinetike. Aleš Mrhar. Prirejeno po. A First Course in Pharmacokinetics and Biopharmaceutics by David Bourne,

BASIC PHARMACOKINETICS

Medication use in children

Developmental Pharmacokinetics of Lamivudine in 580 Pediatric Patients Ranging from Neonates to Adolescents

Modifying Drug Dosing for Patients with Renal Insufficiency

OMCJH.CHEM.COLL.INF.1001 Therapeutic Drug Monitoring Guidelines

The Time Course of Placebo Response in Clinical Trials

Clinical Pharmacology. Pharmacodynamics the next step. Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland, New Zealand

AMINOGLYCOSIDES DOSING AND MONITORING GUIDELINES

Pediatric Pharmacotherapy

Population pharmacokinetic and pharmacodynamic analyses of safinamide in subjects with Parkinson s disease

Pharmacokinetics PCTH 325. Dr. Shabbits September 12, C t = C 0 e -kt. Learning Objectives

Use ideal body weight (IBW) unless actual body weight is less. Use the following equation to calculate IBW:

Outline. What is a VPC? Model Evaluation. What is a Visual Predictive Check? What choices are there in presentation? What can it help to show?

INTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS

Pharmacodynamic principles and the time course of immediate drug effects

Drug Dosing in Renal Insufficiency. Coralie Therese D. Dimacali, MD College of Medicine University of the Philippines Manila

Public Assessment Report. EU worksharing project paediatric data. Valcyte. Valganciclovir

Gentamicin - Ototoxicity in children

Foo Koon Mian Pharmacy Resident National University of Singapore Hematology / Oncology Pharmacy Residency Program. 4th APOPC November 2012

New drugs necessity for therapeutic drug monitoring

PHA Final Exam Fall 2006

A Mechanism-Based PK/PD Model Predicts the Time-Course of Hematological responses for Epoetin beta

Aminoglycosides. Uses: Treatment of serious gram-negative systemic infections and some grampositive

Review article Pediatric models for adult target-controlled infusion pumps

Pharmacokinetics of daptomycin in a patient with severe renal failure not under dialysis

Population Pharmacokinetic Analysis of Digoxin in Chinese Neonates and Infants

Evaluation of a glomerular filtration term in the DISST model to capture the glucose pharmacodynamics of an insulin resistant cohort

AMINOGLYCOSIDES TDM D O N E B Y

PHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

The general Concepts of Pharmacokinetics

AUGMENTED RENAL CLEARANCE and its clinical implications. Professor Jeffrey Lipman

PHARMACOKINETICS SMALL GROUP I:

Renal Excretion of Drugs

PRESCRIBING IN LIVER AND RENAL DISEASE

Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation

ORIGINAL ARTICLE Infectious Diseases, Microbiology & Parasitology INTRODUCTION

Title: Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations

PHA 5128 Spring 2009 First Exam (Version B)

50% Concentrated Injection

Basic Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics

DBL MAGNESIUM SULFATE CONCENTRATED INJECTION

Biomath M263 Clinical Pharmacology

Guidance on competencies for Paediatric Pain Medicine reviewed 2017

Transcription:

Scaling Renal Function in Neonates and Infants to Describe the Pharmacodynamics of Antibiotic Nephrotoxicity Nick Holford University of Auckland Catherine Sherwin University of Utah

Outline What does Scaling of Pharmacodynamics mean? What is GAVamycin? Creatinine Production Rate Glomerular Filtration Rate Renal Function Disease Progression PD of Gavamycin

Scaling, Maturation, Disease Progression Scaling Body mass used to predict body structure and body function differences Allometric theory Maturation Describing maturation of structure and function using biological age Applied with allometric theory to account for body mass Disease Progression Description of changes in disease status with time Pharmacodynamics may change disease progress

Pharmacodynamic Scaling and Maturation Effect Scale (Emax, Slope) Allometric scaling e.g cardiac output, forced expiratory volume, glomerular filtration rate,.. No scaling possible when effect is not related to size e.g. EEG effects, analgesia, antibiotic action, Allometric scaling anti-depressant effect,.. Turnover and Effect Compartment Rates/Half-lives Receptor Affinity (C50) Maturation using biological age to young adult values Ageing changes in older adults (probably no real change in affinity changes more likely related to age associated changes in body function)

GAVamycin Gentamicin Amikacin Vancomycin Three similar antibiotics Eliminated primarily by the renal route Used extensively in neonates and adults Standard size and maturation model approach Holford N, Heo YA, Anderson B. A pharmacokinetic standard for babies and adults. J Pharm Sci. 2013;102(9):2941-52. Germovsek E, Barker CIS, Sharland M, Standing JF. Scaling clearance in paediatric pharmacokinetics: All models are wrong, which are useful? Br J Clin Pharmacol. 2017;83(4):777-90.

Data and Key Question Study Description Location Principal Investigator Patients ALL Pooled gentamicin, amikacin, vancomycin, GFR International Holford & Sherwin STDY4 Glomerular filtration rate International Rhodin et al. (2009) 108 6055 STDY14 Gentamicin Salt Lake City 3209 STDY15 Vancomycin Salt Lake City 2655 STDY16 Amikacin Salt Lake City 83 Can this large data set be used to demonstrate adverse pharmacodynamics effects of these antibiotics on renal function?

Renal Function GFR=FCLcr*CLcr=FCLcr*CPR/Scr agfr=acpr/scr GFR=STDGFR*FSZ GFR *FMAT GFR ; Actual GFR but FClcr unknown ; Apparent GFR with FCLcr=1 ; Normal GFR Size and maturation Renal function (RF) defined as ratio of apparent GFR to normal GFR RF=aGFR/GFR acpr=apparent creatinine production rate estimated by assuming CLcr=GFR STDGFR =6.8 L/h (119 ml/min) from Rhodin et al (2009) updated with neonatal and child FFM predicted using data from Sumpter & Holford (2012)

Computational Methods NONMEM 7.4.1 gfortran 64 bit Wings for NONMEM 742 R to create WFN VPC

Creatinine Production Rate Size

Creatinine Production Rate Maturation

Glomerular Filtration Rate Size

Glomerular Filtration Rate Maturation

Results CPR and GFR Creatinine Production Rate Allometric size exponent=1, Ffat=0 (size fat free mass). Constant up to 44 weeks PMA then linear maturation to 20 years using data of Rhodin et al (2009). Glomerular Filtration Rate Update of Rhodin et al (2009) with better prediction of fat free mass in neonates, infants and children. GFR predicted best by fat free mass. No effect of fat mass. PMA=Post Menstrual Age (estimate of post conception age)

Renal Function Size and Maturation

Neonatal Renal Function Maturation by Drug Gentamicin CPRMAT=CPR20+(1-CPR20)*(1-exp(-T2CPR*(PMA-20)) Vancomycin RF=RFDRUG RF=RFDRUG/CPRMAT

Results Renal Function Renal Function Renal function (median) close to 1 from infancy to adult (30 y). Unexpectedly high renal function in premature neonates can be explained by adding an additional maturation function for CPR. Disease Progress No systematic change in renal function with time. Pharmacodynamics No slope effect of exposure (Dose/CL) on progression. No offset effect of exposure relative to baseline renal function.

Conclusion Creatinine production rate from premature neonates up to young adults can be calculated using fat free mass and post-menstrual age. Maturation of CPR increases rapidly in premature neonates approaching an asymptote at 44 weeks PMA then increases linearly to young adulthood. Renal function in patients treated with vancomycin, amikacin or gentamicin is close to 100% at all ages. No pharmacodynamic effect of antibiotic exposure (AUC) on renal function progression was detectable. Current clinical practice is not associated with a population trend for nephrotoxicity.